PMID- 29728308
OWN - NLM
STAT- MEDLINE
DCOM- 20191114
LR  - 20191114
IS  - 1879-4076 (Electronic)
IS  - 1879-4068 (Linking)
VI  - 9
IP  - 6
DP  - 2018 Nov
TI  - Health related quality of life in older or frail patients with advanced 
      colorectal cancer treated with dose reduced capecitabine.
PG  - 659-664
LID - S1879-4068(18)30140-1 [pii]
LID - 10.1016/j.jgo.2018.04.002 [doi]
AB  - OBJECTIVES: Palliative chemotherapy's role is to prolong survival while 
      minimizing treatment toxicities to preserve or improve quality of life. We have 
      recently published a phase II trial of dose reduced capecitabine in older or 
      frail patients with advanced colorectal cancer (aCRC). We herein provide a robust 
      analysis of the health related quality of life (HRQoL) data from our trial. 
      METHODS: A single arm multi-centered phase II trial of dose reduced capecitabine 
      (1500 or 2000 mg/m(2) days one-fourteen q21 days) in older or frail patients. 
      Participants (182 patients) were asked to complete Functional Assessment of 
      Cancer Therapy general questionnaire (FACT-G) at enrollment, after each cycle of 
      capecitabine, and once upon completion, if possible. RESULTS: 157 patients 
      completed a baseline questionnaire (86%), and 137 patients (75%) completed at 
      least one subsequent questionnaire. The mean baseline score was 81.6, out of a 
      possible 108. The mean score peaked at 92 after cycle 10. The mean change from 
      baseline was always positive. Patients achieving the minimal clinically important 
      difference (MCID) ranged from 30% to 45% during treatment. Higher baseline FACT-G 
      and Physical Well-being score were independently prognostic for improved survival 
      (p = 0.006 and p < 0.0001, respectively). Time until definitive deterioration 
      (TUDD) was insignificantly longer in patients with a higher baseline FACT-G 
      (p = 0.18). CONCLUSION: Baseline HRQoL scores were independently prognostic for 
      survival, supporting their importance. Compared to full dose, reduced dose 
      capecitabine has previously demonstrated equivalent efficacy and reduced 
      toxicity. We have reported dose reduced capecitabine improves quality of life in 
      older or frail patients with aCRC, further supporting its use in the management 
      of aCRC.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Breadner, Daniel
AU  - Breadner D
AD  - London Regional Cancer Program, London, Ontario, Canada; Schulich School of 
      Medicine and Dentistry, London, Ontario, Canada. Electronic address: 
      Daniel.breadner@lhsc.on.ca.
FAU - Vincent, Mark David
AU  - Vincent MD
AD  - London Regional Cancer Program, London, Ontario, Canada; Schulich School of 
      Medicine and Dentistry, London, Ontario, Canada.
FAU - Jonker, Derek
AU  - Jonker D
AD  - Department of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, 
      Ontario, Canada.
FAU - Cripps, Christine
AU  - Cripps C
AD  - Department of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, 
      Ontario, Canada.
FAU - Klimo, Paul
AU  - Klimo P
AD  - Medical Oncology, Lions Gate Hospital, North Vancouver, British Columbia, Canada.
FAU - Biagi, James
AU  - Biagi J
AD  - Department of Oncology, Queen's University, Kingston, Ontario, Canada.
FAU - Lam, Wendy
AU  - Lam W
AD  - Burnaby Hospital Cancer Centre, Burnaby, British Columbia, Canada.
FAU - O'Connell, Anne
AU  - O'Connell A
AD  - London Regional Cancer Program, London, Ontario, Canada.
FAU - Whiston, Frances
AU  - Whiston F
AD  - London Regional Cancer Program, London, Ontario, Canada.
FAU - Stitt, Larry
AU  - Stitt L
AD  - London Regional Cancer Program, London, Ontario, Canada.
FAU - Welch, Stephen
AU  - Welch S
AD  - London Regional Cancer Program, London, Ontario, Canada; Schulich School of 
      Medicine and Dentistry, London, Ontario, Canada.
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180502
PL  - Netherlands
TA  - J Geriatr Oncol
JT  - Journal of geriatric oncology
JID - 101534770
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 6804DJ8Z9U (Capecitabine)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Antimetabolites, Antineoplastic/*administration & dosage
MH  - Capecitabine/*administration & dosage
MH  - Colorectal Neoplasms/*drug therapy/mortality/*psychology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Frailty/mortality/*psychology
MH  - Humans
MH  - Male
MH  - *Quality of Life
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Advanced colorectal cancer
OT  - Capecitabine
OT  - HRQoL
OT  - Time until definitive deterioration
EDAT- 2018/05/08 06:00
MHDA- 2019/11/15 06:00
CRDT- 2018/05/06 06:00
PHST- 2017/11/13 00:00 [received]
PHST- 2018/03/02 00:00 [revised]
PHST- 2018/04/05 00:00 [accepted]
PHST- 2018/05/08 06:00 [pubmed]
PHST- 2019/11/15 06:00 [medline]
PHST- 2018/05/06 06:00 [entrez]
AID - S1879-4068(18)30140-1 [pii]
AID - 10.1016/j.jgo.2018.04.002 [doi]
PST - ppublish
SO  - J Geriatr Oncol. 2018 Nov;9(6):659-664. doi: 10.1016/j.jgo.2018.04.002. Epub 2018 
      May 2.